Librarian Capital's Research Library

Librarian Capital’s Research Library

Zoetis: Bad Q3, But Not for the Reasons Many Think

Company Update (ZTS US) (Buy): The idea Zoetis has gone ex-growth due to new rivals for Apoqel and Simparica, and Librela failure, is likely wrong.

Librarian Capital's avatar
Librarian Capital
Nov 10, 2025
∙ Paid

Highlights

  • Q3’s main problem is zero growth in U.S. Companion Animal revenue.

  • Apoquel and Simparica were culprits; some blame new rival products.

  • We believe share losses were minor and growth will reaccelerate.

  • Some near-term uncertainty, but risk/reward attractive at ~20x P/E.

  • At $120.24, we see 77% total return (20.3% p.a.) by 2028 end. Buy.

Introduction

Zoetis released Q3 2025 results last Tuesday (November 4), and shares have fallen 16.7% in the subsequent 4 days; they are now down ~40% from their last peak in late 2024, and 27% lower than 5 years ago:

Zoetis Share Price (Last 5 Years)

Source: Google Finance (09-Nov-25).

Zoetis is a mid-sized position in our “Select 15” model portfolio, initiated in June and expanded in October; this is currently showing a 19.5% loss. Prior to this, we had made a profitable roundtrip in Zoetis shares for the model portfolio in early 2023, and several more in real life. We bought substantially more Zoetis shares in real life last week.

Companion Animal revenues decelerated in Q3, and Q4 guidance implies another weak quarter. It is easy to blame these on Key Dermatology and Simparica losing market share to new rivals as well as on bad publicity around Librela, but macro headwinds likely had more impact. There is near-term uncertainty, but overall risk/reward is attractive.

(The rest of this article is for paid subscribers only, but unlocking it costs just $10; you can see a free sample of our research here.)

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2026 Librarian Capital · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.